Imatinib Mesylate Tablet, Film Coated
FDA Label NDC 0093-7629

74 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Imatinib Mesylate (NDC 0093-7629). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 newly diagnosed philadelphia positive chronic myeloid leukemia (ph+ cml), 1.2 ph+ cml in blast crisis (bc), accelerated phase (ap) or chronic phase (cp) after interferon-alpha (ifn) therapy, 1.3 adult patients with ph+ acute lymphoblastic leukemia (all), 1.4 pediatric patients with ph+ acute lymphoblastic leukemia (all), 1.5 myelodysplastic/myeloproliferative diseases (mds/mpd), 1.6 aggressive systemic mastocytosis (asm), 1.7 hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukemia (cel), 1.8 dermatofibrosarcoma protuberans (dfsp), and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.